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Abstract 
RECQL4 is a gene that encodes a 1208 amino acid protein. RECQL4 protein is required during 
DNA replication initiation and DNA end resection. A lack of RECQL4 is therefore associated 
with a decrease in DNA damage repair. There are three unrelated autosomal recessive 
diseases that are linked with mutations in RECQL4. Rothmund Thomson Syndrome is rare 
disorder which has documented mutations within RECQL4 which has been linked to an 
increased tendency to develop osteosarcomas.  
To study the effect of RECQL4 depletion, shRNA knockdowns, ASC52Telo cells, osteo-
differentiated cells and osteo-differentiated cells in long term PHA-767491 treatment were 
subjected to a series of experiments. The trilineage differentiation capability, growth 
characteristics, expression of cell proliferation and bone formation markers, drug sensitivity 
and chromosomal instability was tested for each of the cell lines. These results could be used 
to identify any differences in expressions and behaviours between the RECQL4 depleted cells 
and the control cells. 
All the cell lines were able to differentiate into adipocytes and osteoblasts, with p44 pLK0.1 
and p44 shRQ-9 having a decreased adipocyte differentiation in comparison to the others. No 
significant difference was observed in the growth assay between the cells in which RECQL4 
was depleted and their controls. The p44 shRQ-9 cells showed the lowest foci count when 
tested for 53BP expression but the highest Ki67 expression. There were no significant results 
between the RECQL4 depleted cells and their controls when looking at marker gene 
expressions. The drug sensitivity assays also show no significant differences however p14 
shRQ-10 and P44 shRQ-10 appear less sensitive in the mid-range concentrations. The 
chromosomal analysis showed that OD+PHA, p44 shRQ-9 and p44 shRQ-10 have an increased 
degree of aneuploidy and tetraploid cells.   
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1. Introduction 
1.1 Mesenchymal Stem cells 
Evidence was first provided by Friedenstein et al. (1970) that a population of hematopoietic 
stem cells (HSCs) and a rare population of plastic-adherent cells was present in the bone 
marrow (BM). During the 1980’s it was shown that mesenchymal stem cells (MSCs) had the 
capability of differentiating to osteoblasts, chondrocytes and adipocytes (Williams and Hare, 
2011). Since then MSCs have been shown to be present in a variety of foetal and adult tissues 
including cord blood, amniotic fluid, foetal blood and, in some cases, adult peripheral blood. 
Many researchers have had a keen interest in MSCs due to their therapeutic potential in tissue 
repair and immune modulation (Roberts, 2004). Owing to their ease of isolation, expansion 
and their multi-lineage differentiation ability, MSCs are applied in a range of experimental and 
medical applications. Some examples include the enhancement of HSC engraftment, the 
amelioration of acute graft-versus-host disease and regenerative medicine approaches, in 
particular for bone and cartilage ((Xiao et al., 2013) 
1.1.1 MSC defining Characteristics 
A universal definition of an MSC is difficult to decide on since there are no unique 
unambiguous cell surface markers to distinguish MSCs from HSCs. When undifferentiated, the 
shape of MSCs resemble the spindle shape of fibroblasts making them hard to distinguish 
(Williams and Hare, 2011). Stem cells have traditionally been defined by their multipotency 
and self-renewal capability (Nombela-Arrieta et al., 2011).  Some researchers are unsure 
whether MSCs are true stem cells or multipotent precursor cells. A standard criteria has been 
developed by the International Society of Cellular Therapy that defines MSCs by three 
characteristics: “1) adherence to plastic in standard culture conditions, 2) expression of CD105, 
CD73  and CD90 and no expression of CD45, CD34, CD14, CD11b, CD79b, CD19 and HLA-DR 
and 3) capacity to differentiate into osteoblasts, chondroblasts and adipocytes in vitro, termed 
trilineage differentiation potential” (Xiao et al., 2013).  
Phenotypically, MSCs express many different markers, although none of these are specific to 
MSCs. However, cell surface CD markers can be used to distinguish between MSCs and HSCs. 
For example MSCs lack the haematopoietic markers CD34, CD45, CD14, CD11 and HLA-DR. 
MSCs can also express markers including myofibroblasts, neurons and transforming growth 
factor-β (TGF-beta) (Ding et al., 2011). As well as the adhesion molecules mentioned in the 
standard criteria, MSCs also express some cytokine receptors (e.g. IL-1R, TNF-αR) and some 
stromal cell markers (e.g. SH-2, SH-3 and SH-4) (Roberts, 2004, Chamberlain et al., 2007).  
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1.1.2 Sources of MSCs 
MSCs can be obtained from various tissues including the umbilical cord, endometrial polyps, 
bone marrow, peripheral blood, skeletal muscle and adipose tissue (Ding et al., 2011, Wagner 
et al., 2005). These are ideal sources due to the quantity that can be obtained and ease of 
harvesting the cells (Ding et al., 2011). The most researched and most accessible source of 
MSCs is the BM, even though the number of cells present are low in frequency (0.01-0.0001% 
of nucleated cells in BM) (Roberts, 2004). Although BM represents the main source of MSCs, 
the number of BM MSCs available decreases with age and can be affected when there is a high 
degree of viral infection. Obtaining BM MSCs from a patient is also a highly invasive procedure, 
making it necessary to look for alternative sources of MSCs (Romanov et al., 2003, Kern et al., 
2006).  
Recently it has been shown that stem cells can be derived from the umbilical cord matrix and 
blood. Umbilical cord blood (UCB) is a much less invasive method that causes no harm to the 
mother of the infant (Kern et al., 2006). It is established that UCB is a rich source of HSCs, but 
the ability to establish MSC cultures from UCB is controversial. Some studies have proven to 
isolate MSCs from UCB at a sufficient yield to use in clinical application, but other studies have 
clearly failed (Zeddou et al., 2010). Researchers from Kansas State University concluded that 
cells from the matrix of the umbilical cord (UCM) had stem cell properties and thus could 
prove a rich source of primitive cells (Mitchell et al., 2003), with Zeddou et al. (2010) 
confirming it is possible to isolate MSCs from UCM in their experiment. 
Most of the evidence obtained so far suggests the MSCs are not present in the peripheral 
blood of healthy adults, only in specific circumstances. These can include patients with 
malignant diseases and healthy women during and after pregnancy (Roberts, 2004). There is, 
however, evidence that MSCs can be collected from menstrual blood (Ding et al., 2011). 
Around 400 menstrual cycles occur in each women’s reproductive years, with the average 
blood loss each menstruation around 35ml (Ding et al., 2011, Toyoda et al., 2007). Menstrual 
blood is usually discarded but could represent a new source of human MSCs to be used in 
regenerative medicine (Ding et al., 2011). Many of MSCs collected from this source have 
myogenic differentiation potential, especially towards forming cardiac muscle cells (Toyoda et 
al., 2007).  
Another alternative source of stem cells, which is less invasive and available in larger 
quantities, is adipose tissue (Kern et al., 2006). With the current increase in obesity across the 
world, subcutaneous adipose tissue is easily accessible and in abundance. Thousands of 
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liposuction surgeries are carried out each year and the lipoaspirate tissue is discarded (Bunnell 
et al., 2008). In the past a variety of names have been used to try and describe that plastic 
adherent cell population that can be isolated from adipose tissue. To help avoid confusion, the 
International Fat Applied Technology Society adopted the term “adipose-derived stem cells” 
(ASCs) to describe this cell population (Bunnell et al., 2008). ASCs are pluripotent cells with 
characteristics similar to BM-derived MSCs. Studies have shown that ASCs contain similar 
surface markers and gene profiling to the MSCs found in BM (Kim et al., 2007). 
1.1.3 Differentiation of MSCs 
As mentioned before, MSCs have the ability to differentiate into a variety of lineages of 
mesodermal origin. Their tri-lineage potential to differentiate into bone, cartilage and fat in 
vitro can be used to further help identify MSC populations (Ding et al., 2011).  
To promote adipogenesis differentiation, MSCs are induced through incubation with 
dexamethasone, insulin, isobutyl-methylxanthine and indomethacin for a period of 2-3 weeks. 
An accumulation of lipid-rich vacuoles within the cells can be seen which express peroxisome 
proliferation-activated receptor ƴ2, lipoprotein lipase and aP2: a fatty acid-binding protein 
(Pittenger et al., 1999). These lipid vacuoles can be assayed histologically by staining lipid 
droplets in cells using Oil Red O solution (Figure 1A) (Ding et al., 2011). These adipocytes were 
shown to remain healthy for at least 3 months in culture (Pittenger et al., 1999).  
Osteogenic differentiation has been widely induced in vitro by incubating a confluent 
monolayer of MSCs with a mixture of dexamethasone, β-glycerophosphate and ascorbic acid 
phosphate for a period of 2-3 weeks (Chamberlain et al., 2007). A study by Pittenger et al. 
(1999) showed the isolated MSCs formed aggregates which could be viewed by staining with 
Alizarin Red (Figure 1B). Any osteo-differentiation MSCs stain a bright orange-red colour. Their 
quantitative assays also showed that there was a 4-10 fold increase in alkaline phosphatase 
activity and that after 1 week of incubation there was evidence of calcium accumulation 
(Pittenger et al., 1999). 
Chondrogenic differentiation is promoted through the culturing of MSCs in the presence of 
TGF-β. Histological analysis using toluidine blue indicated the presence of glycosaminoglycans 
within the extracellular matrix (Chamberlain et al., 2007). The presence of glycosaminoglycans 
can also be shown with Alcian Blue staining (Figure 1C). 
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Figure 1. Trilineage potential of MSCs. Differentiation of MSCs into A) Adipocytes stained with Oil Red O, B) 
Osteoblasts stained with Alizarin Red and C) Chondrocytes stained with Alcian Blue (Dolley-Sonneville et al., 2013). 
Previous studies have also demonstrated that BM-derived MSCs have the ability to 
differentiate into myoblasts that can fuse into rhythmically beating myotubes, after treatment 
with 5-azacytidine and amphotericin B (Wakitani et al., 1995).  
All these differentiation events are accompanied by changes in gene expression and are tightly 
regulated by signalling events and transcription factors (Ding et al., 2011). 
1.1.3.1 Regulation of differentiation 
There are two main molecular pathways that describe the regulation of the differentiation of 
MSCs into cartilage and bone: the WNT canonical pathway and the TGF-β superfamily pathway 
(Augello and De Bari, 2010). It is likely that many different growth factors will interact with 
these pathways to help control MSC differentiation (Williams and Hare, 2011). 
The TGF-β pathway is involved in skeletal growth and the regulation of the chondrogenic 
differentiation of MSCs. TGF-β3 promotes chondrogenic differentiation in MSCs via several 
intracellular cascades, including the SMAD proteins, mitogen-activated protein kinases and 
extracellular-signal regulated kinases (Williams and Hare, 2011).  
WNT glycoproteins are soluble glycoproteins that activate receptor complexes composed of 
Lrp5 and Lrp6 proteins, which induces a series of intracellular events that monitor cell 
differentiation and proliferation (Westendorf et al., 2004). This WNT pathway has been shown 
to play an important role during skeletogenesis by promoting osteoblast proliferation and 
suppressing chondrocyte formation (Westendorf et al., 2004). WNT signalling leads to the 
stimulation of four different signalling pathways, the canonical pathway being the best 
characterised (Etheridge et al., 2004). This pathway regulates β-catenin stability, an integral 
part in transducing WNT signals to the nucleus (Westendorf et al., 2004). Disruptive mutations 
in the LRP5 receptor have been associated with a decreased bone mass and decreased 
osteoblast proliferation, whereas activating mutations in LRP5 can result in a high bone-mass 
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phenotype and increased osteoblast proliferation (Etheridge et al., 2004). There are a number 
of WNT ligands and receptors expressed on MSCs, each controlling MSC differentiation. For 
example WNT3A promotes undifferentiated MSC proliferation and suppresses osteogenic 
differentiation (Boland et al., 2004).  
 
Figure 2. Molecular regulation of MSC differentiation. WNT and TGF-β signalling pathways that regulate 
differentiation of MSCs (Adapted from (Williams and Hare, 2011) using PowerPoint). 
One of the genes shown to be a target of β-catenin is runt-related transcription factor 2 
(RUNX2), resulting in the stimulation of bone formation (Gaur et al., 2005). RUNX2 plays an 
essential role in osteoblast differentiation and during the later stages of chondrocyte 
differentiation. RUNX2 has been shown to upregulate osteoblast-related genes such as ALP, 
BGLAP, OCN, BSP and COL1A1 (Florencio-Silva et al., 2015). Another transcription factor 
involved in the regulation of bone formation and osteoblast differentiation is zinc finger 
transcription factor Osterix , which has been shown to be regulated by RUNX2 (Nishio et al., 
2006).  RUNX2 is the first transcription factor required to determine the osteoblast lineage, 
with canonical WNT signalling and Osterix further directing the outcome by blocking their 
differentiation into chondrocytes (Komori, 2008). 
1.1.4 Therapeutic uses of MSCs 
Due to their tri-lineage potential, ease of expansion and isolation, MSCs have therapeutic 
potential in a variety of medical applications. The ability of MSCs to maintain pluripotency 
after prolonged culturing offers the use of cultured MSCs in autologous and allogeneic 
transplants. Other medical applications that have seen the use of MSCs are in cardiac repair, 
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reducing graft-versus-host disease, enhancing marrow engraftment and in generating 
connective tissue elements that may be abnormal (Ng et al., 2008). The immunological 
characteristics of MSCs further enhance their therapeutic appeal (Javazon et al., 2004). 
1.1.5 Immunological characteristics of MSCs 
The immunological phenotype of MSCs is widely described as MHC I+, MHC II-, CD40-, CD80- 
and CD86-. This phenotype is regarded as non-immunogenic and therefore when used in 
transplantations, the allogeneic host may not require the use of immunosuppression. It is 
possible that MHC class I may activate T cells, but due to the absence of any costimulatory 
modules there would be no secondary signal (Javazon et al., 2004). There have been multiple 
studies that suggest MSCs have immunosuppressive properties, in particular that MSCs have 
the ability to modulate many T-cell functions, including cell activation. However, this 
suppression is independent of any MHC matching between the T cells and MSCs (Chamberlain 
et al., 2007).  
1.1.6 hTERT immortalisation of MSCs 
Human cell lines that have been derived from non-cancerous tissues have a finite lifespan 
when cultured under laboratory conditions meaning senescence occurs after a limited number 
of divisions. This limitation to the cell lines has proved to be a major obstacle in previous 
experiments and it also limited their use as therapeutic agents. Multiple forms of senescence 
have been shown to exist with telomere-controlled senescence proving a common form (Lee 
et al., 2004). The onset of telomere senescence is shown through the shortening of the 
telomeres. Telomeres shorten each time cell division occurs, providing a “molecular clock” for 
cell lines (Bernadotte et al., 2016).  This shortening ultimately leads to mortality stage 1 (M1) 
and stage 2 (M2). It has been shown that in cells of renewal tissues a DNA polymerase, named 
telomerase, is present and has the ability to synthesise telomeric repeats, which compensates 
for the end replication problem that is caused by the shortening of telomeres (Bernadotte et 
al., 2016). Telomerase is made up of two core components: human Telomerase Reverse 
Transcriptase (hTERT) and human Telomerase RNA (hTR). The first core component is involved 
in providing catalytic activity, and its expression is normally suppressed in human somatic cells. 
When expressed exogenously it can sufficiently reconstitute telomerase activity, preserving 
the length of the telomeres and ultimately preventing the onset of M1 and M2 (Lee et al., 
2004).  
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1.1.7 Osteoblasts to Osteocytes  
Osteoblasts are defined as bone forming cells that originated from MSCs. They are found along 
the bone surface and make up 4-6% of the composition of bone cells (Florencio-Silva et al., 
2015). Osteoblast cells secrete osteoid, a non-mineralised bone matrix, and become 
incorporated in mineralised bone matrix as osteocytes (Franz-Odendaal et al., 2006). 
Osteocytes comprise 90-95% of all bone cells, making them undoubtedly the most abundant 
cellular component of mammalian bones (Feng et al., 2006, Franz-Odendaal et al., 2006). The 
morphology of osteocytes depends on the type of bone. For example, osteocytes found in the 
trabecular bone are more rounded in appearance in comparison to those found in cortical 
bone. It is suggested that osteocytes on average have a half -life of around 25 years, much 
greater than the average lifespan of an osteoblasts which is only three months. (Florencio-Silva 
et al., 2015). Osteocytes have the ability to communicate not only with one another, but with 
all cells present at the bone surface through a meshwork of cell processes in the bone matrix 
that run through canaliculi (Palumbo et al., 1990). This ensures that all cells involved in the 
formation of bone remain connected during all stages (Franz-Odendaal et al., 2006)  
There are three different modes of ossification that transform osteoblasts into osteocytes; 
intramembranous, perichondral and endochondral. The mode used is dependent on what type 
of bone is being generated (woven or lamellar bone), the location of bone formation and the 
age/gender of the individual. Intramembranous bone formation forms membrane bones and 
occurs when bone is formed without the replacement of a cartilaginous model. In the presence 
of a cartilaginous precursor, perichondral ossification is the most common mode of bone 
formation. Endochondral ossification is normally seen in long bones and involves a 
cartilaginous template that is either remodelled or is replaced by bone through a series of co-
ordinated steps (Franz-Odendaal et al., 2006). 
There are four different fates for osteoblasts at the end of a bone-forming phase. They can 
become osteocytes embedded in the bone, become bone lining cells, undergo apoptosis or 
occasionally transdifferentiate into cells that deposit chondroid bone (Franz-Odendaal et al., 
2006). Parfitt (1990) reported that 65% of osteoblasts in cancellous bone undergo apoptosis 
and around 30% undergo osteocyte transformation.  
1.2 Osteosarcoma- Tumours of the bone 
Osteosarcoma is the most prevalent malignant bone tumour which is presumed to derive from 
cells of an osteoblastic lineage. It is characterised by the production of immature osteoid by 
neoplastic cells (Poos et al., 2015). Osteosarcoma most often presents itself in the femur (42% 
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with 75% occurring in the distal femur), humerus (10% with 90% in the proximal humerus) or 
the tibia (19% with 80% occurring in the proximal tibia) of patients. The age distribution of 
osteosarcoma is defined as bimodal, the first peak being during adolescence and the second 
peak during late adulthood (Ottaviani and Jaffe, 2010). The first peak normally occurs in the 
pubertal growth spurt in 10-14 year olds. The deaths due to osteosarcoma represent 8.9% of 
childhood and adolescent cancer deaths. The average 10 year survival rate is currently just 
over 65.8%, but only 24% in patients with formed metastases at the time of presentation 
(Duchman et al., 2015). Elderly patients have the poorest survival chances (Ottaviani and Jaffe, 
2010). There are many factors affecting the prognosis of osteosarcoma, a few of the factors 
being response to chemotherapy, presence of metastases, tumour site and tumour size (Clark 
et al., 2008). The current therapy to manage osteosarcoma consists of preoperative 
chemotherapy, complete surgical resection and postoperative chemotherapy. Owing to the 
advances in imaging techniques and the positive effect of the use of preoperative 
chemotherapy, amputation of the affected limb is rarely required as surgery can normally be 
limb-sparing (Luetke et al., 2014). 
Molecular markers and pathways that help contribute to the development of osteosarcoma 
have been a recent area of research to determine their significance as clinically predictive 
tools. These markers can be useful in predicting a patient’s response to chemotherapy, the 
overall prognosis and developing therapeutic agents to help with the treatment (Clark et al., 
2008). 
1.2.1 Molecular markers in osteosarcoma 
The current standard prognostic markers carry a level of inaccuracy and bear a number of 
limitations. This has presented the need for quantitative measures to help improve treatment 
planning. The table below outlines some of the molecular factors that have been associated 
with the prognosis of osteosarcoma (Clark et al., 2008). 
Table 1. Molecular factors shown to be associated with the prognosis of osteosarcoma. Modified from Clark et al. 
(2008). 
Factor Role in osteosarcoma Level present 
in 
osteosarcoma 
Any 
correlation 
with 
prognosis? 
Potential for 
therapeutic 
use 
VEGF Angiogenesis ↑ Controversial Yes 
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
9 
 
MMP2, 
MMP9 
Extra-cellular matrix 
invasion 
↑ Correlation Yes, positive 
results from 
other cancers 
PLAU/PLAUR Increases plasmin. Pro 
invasion 
↑ Correlation Yes, reduced 
invasion when 
regulated 
P-glycoprotein Drug resistance ↑ Correlation Undetermined 
CXCR4 Chemotaxis, organ 
specific metastasis 
↑ Correlation Yes 
TP53 Cell cycle control ↓/mutated Correlation Undetermined 
ERBB2 Cell signalling, 
proliferation 
Mixed results Controversial Undetermined 
Survivin Inhibits apoptosis ↑ Correlation Undetermined 
HLA class I Absence allows 
immune system 
invasion 
↓ Correlation Undetermined 
Ezrin Cell signalling, 
metastasis 
↑ Correlation Yes 
RB1 Tumour suppressor ↓/mutated Correlation Undetermined 
FOS Transcription ↑ Indirect 
correlation 
Undetermined 
 
1.2.2 Genomic instability in osteosarcoma 
Genomic instability has been shown to play a critical role in the development and progression 
of cancer, and has also shown to have implications on the aging progress (Petkovic et al., 
2005). Osteosarcoma exhibits a complex karyotype due to the high levels of genomic 
instability, particularly chromosomal instabilities (Poos et al., 2015). Over the years, many 
cytogenetic studies and genomic analyses of osteosarcomas have been carried out using 
multiple techniques such as karyotyping, comparative genomic hybridisations, quantitative 
PCR and many others. More recently, studies utilising single-nucleotide polymorphisms (SNPs) 
have been carried out to understand more about osteosarcoma genomics. There is still a lot of 
uncertainty around the genetic etiology, but there are some consistent findings. Many studies 
have shown that there is a higher prevalence to develop osteosarcoma in individuals with 
familial Li-Fraumeni syndrome (TP53 inactivation), Rothmund-Thomson syndrome (RECQL4 
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inactivation), Bloom syndrome (BLM inactivation) and Werner syndrome (WRN inactivation). 
The genes linked with these latter three syndromes encode DNA helicases of the RecQ family, 
involved in the maintenance of DNA (Martin et al., 2012). 
Osteosarcoma is susceptible to aneuploidy with a large number of chromosomal alterations 
being present (Nishijo et al., 2004). Previous cytogenic analysis of the cancerous cells in 
osteosarcoma has shown a clear change in the number of chromosomes and a tendency to 
develop structural chromosomal aberrations. (Al-Romaih et al., 2003). There are two subtypes 
of chromosomal instability (CIN): numerical CIN and structural CIN. The processes resulting in 
numerical CIN are those that result in copy number alterations. It is evident in polyploidy 
which can be caused by errors in mitosis, deletions, amplifications, translocations and 
aneuploidy. Structural CIN normally results from ineffective DNA damage response 
mechanisms induced by genotoxic insults, replication errors that can lead to chromosomal 
breakages and genomic rearrangements.  
1.2.3 Mutations linked with osteosarcoma 
The pathogenesis of osteosarcoma has previously been linked to mutations in several genes 
including RB1 and TP53, genes important for mitotic checkpoints (Cao et al., 2005, Maire et al., 
2009). It has also been shown that there is a significant correlation between the mutation of 
TP53 and increased levels of genomic instability in osteosarcoma, while studies involving RB1 
mutation show a contribution to the loss of heterozygosity in mice (Overholtzer et al., 2003, 
Coschi et al., 2010). A study by Maire et al. (2009) of 18 osteosarcoma cases showed a link 
between the overexpression of RECQL4, a gene that encodes a DNA helicase, and structural 
CIN. However, there are many studies suggesting other genes that may contribute to the 
development of osteosarcoma.  
1.3 DNA damage and repair: the role of DNA helicases 
During DNA replication, recombination and repair double stranded DNA must become partially 
unwound to form single stranded DNA intermediates (Lohman, 1993). DNA helicases are 
ubiquitous enzymes responsible for unwinding double stranded DNA and are involved in many 
of the cells basic cellular processes (Wang et al., 2003). DNA helicases utilise the energy 
produced from the hydrolysis of ATP to play an important role in DNA metabolism, 
participating in replication, transcription, repair and chromatin organisation (Croteau et al., 
2012, Mohaghegh and Hickson, 2001).  It is possible that any interruptions to the function of 
these helicases could reduce genomic stability resulting in an increased chance of 
tumorigenesis (Wang et al., 2003).  
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1.3.1 RecQ family helicases 
Helicases of the RecQ family play a critical role in ensuring efficient repair of DNA damage. 
RecQ helicases are members the SF2 superfamily involved in the resolution of DNA structure 
and travel in a 3’-5’ direction on single stranded DNA (Bernstein et al., 2010).   
There are five known RecQ homologues in humans and germ-line mutations in three of these 
are linked with premature aging and/or cancer predisposition (Bachrati and Hickson, 2003).  
RecQ proteins contain many different structural domains with all containing a core helicase 
domain. WRN, BLM and RECQ1 contain a helicase and RNAse D C-terminal (HRDC) and nuclear 
localisation sequences and all except RECQL4 contain a RecQ C-terminal (RQC) domain. It is 
thought that the HRDC and RQC domains are involved in the mediation of interactions with 
nucleic acids and other proteins. All the RecQ helicases except RECQL5 contain an acidic 
region, which enables protein-protein interactions. WRN is the only human RecQ protein that 
contains an exonuclease domain (Figure 3) (Bernstein et al., 2010).  
 
Figure 3. The structural domains of each member of the human RecQ helicases. Adapted from Bernstein et al. 
(2010). 
RecQ helicases are also important at various steps during DNA replication. The absence of 
RecQ helicase activity can result in stalled or collapsed replication forks, which requires 
repairing in order to prevent double strand breaks (DSBs). RecQ helicases can help the 
association of polymerases with the replication fork and unwind any DNA structures that could 
ultimately lead to replication fork stalling. 
1.3.2 RECQL4 
The RECQL4 gene encodes an 1208 amino acid protein and is located on human chromosome 
8q24.3 (Kitao et al., 1999, Wang et al., 2003). Although RECQL4 displays many domain 
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characteristics of the RecQ family, it lacks some features such as the domains that are used in 
DNA binding. Many previous experiments have shown that RECQL4 is required to assemble the 
machinery used in DNA replication initiation (Sangrithi et al., 2005). A study by Im et al. (2015) 
showed that RECQL4 is required during DNA replication initiation for Mcm10 and Ctf4 to 
associate with replication origins. Mcm10 and Ctf4 are crucial parts of the pre-replication 
complex and they are responsible in the recruitment of RECQL4 into the pre-replication 
complex to subsequently initiating replication. A lack of RECQL4 would prevent DNA 
replication initiation from occurring.  
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Figure 4. Schematic diagram showing the assembly of the pre-replication complex. (Adapted by 
Csanad Bachrati from (Diffley, 2004, Labib, 2010, Symeonidou et al., 2012). 
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RECQL4 has been shown to have intrinsic ATPase activity and also single stranded DNA 
annealing activity (Singh et al., 2010). A study by (Lu et al., 2016)) identified a role for RECQL4 
in DNA end resection, an essential step of homologous recombination dependent DNA double 
strand break repair. When a depletion of RECQL4 is seen, there is a subsequent reduction in 
homologous recombination mediated repair and end resection. An interaction is seen between 
RECQL4 and MRE11-RAD50-NBS1 (MRN), which identifies DSBs and initiates DNA end resection 
with the recruitment of CtIP. RECQL4 is also seen directly interacting with CtIP at DSBs via its 
N-terminal domain, recruiting CtIP to the MRN complex (Lu et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3 DNA damage 
DNA damage occurs in many different forms and can result from defects in any part of DNA 
metabolism. In response to DNA damage, cells have developed a range of pathways to arrest 
the cell cycle and induce DNA repair (Mohaghegh and Hickson, 2001). Mutations can 
frequently occur in DNA repair genes, which results in genome destabilisation, consequently 
causing an increase in mutations at other loci. The maintenance of genomic stability is 
Figure 5. The role of RECQL4 in DSB repair. Adapted from Lu et al. (2016). 
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important in the prevention of cancer due to the importance of integrity of the proto-
oncogenes and tumour suppressor genes. This maintenance aims to eliminate spontaneous 
DNA damage through intrinsic errors in DNA metabolism and through DNA reactive agents 
(Mohaghegh and Hickson, 2001). 
One form of DNA damage is double strand breaks (DSBs). These can be generated through 
exogenous stress and programmed recombination events (Lu et al., 2016). They occur when 
the sugar-phosphate backbone of both DNA strands are broken in a close proximity allowing 
the dissociation of the helix into two molecules (Aparicio et al., 2014). DSBs can occur 
accidentally during normal metabolism or because of the presence of DNA-damaging agents. It 
is important that these DSBs are repaired in order to maintain genome integrity and prevent 
chromosome rearrangements or cell death (Symington, 2014). There are two main pathways 
normally used to repair DSBs: homologous recombination (HR) and non-homologous end 
joining (NHEJ) (Aparicio et al., 2014). HR-dependent double strand break repair is on the most 
part error free. This method of repair requires either a sister or non-sister chromatid as a 
template and is only active during G2 and S phases (Lu et al., 2016). Initiation of HR-dependent 
double strand break repair is by the 5’ end resection of DSBs, generating 3’ single strand DNA 
(ssDNA) tails. These subsequently become coated in RPA, an ssDNA binding protein. RAD52 
then recruits RAD51 to replace RPA and promote strand invasion leading to D loop formation 
(Bernstein et al., 2010). This leads to repair synthesis, ligation of the ends and the 
dissolution/resolution of Holliday junctions. On the other hand, NHEJ is error prone but is 
active during all phases of the cell cycle and DNA template-independent (Lu et al., 2016).  
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Figure 6. Homologous recombination. A simplified view of the execution step of homologous recombination repair 
of double-stranded DNA breaks to indicate the position and role of proteins used as functional markers (Created by 
Csanad Bachrati). 
1.3.4 Genotoxic insult to cells 
Many common clinical drugs have cytotoxic effects on cells resulting in DNA damage and can 
result in structural CINs. When treated with these drugs cells can normally rescue themselves 
from the DNA damage. If the cells are RECQL4 deficient then end resection doesn’t occur, 
preventing homologous recombination.  
Bleomycin is an anticancer drug comprising of complex of water-soluble peptides which are 
extracted from Streptomyces verticillatus. It is considered an effective agent in the control of 
numerous human cancers (Adamson and Bowden, 1974). The use of bleomycin can affect 
many different cellular pathways, but the cause of its cytotoxic effect is through its ability to 
bind and cleave DNA. A number of studies also report that bleomycin produces reactive 
oxygen radicals, which when released can result in the expression of cytokines, subsequently 
inducing chromosomal aberrations, DNA strand breaks and DNA damage (Mishra et al., 2000).  
Another cytotoxic agent is Mitomycin C, is a bifunctional DNA alkylating agent that is used in 
cancer treatment. Mitomycin C induces the cross-linking of complementary strands of DNA, 
and it is these cross-links that are considered the critical cytotoxic lesions produced from its 
use (Palom et al., 2002).  
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Camptothecin is a strong anti-tumour drug that inhibits DNA and RNA synthesis resulting in 
fragmentation of cellular DNA. Its intracellular target is topoisomerase I, an enzyme that plays 
a key role in DNA replication, transcription and segregation. Camptothecin binds to both the 
topoisomerase and the DNA complex, forming a ternary complex. This binding prevents the re-
ligation step of topoisomerase action, causes S phase arrest and subsequently results in 
apoptosis (Ryan et al., 1991).   
Hydroxyurea has been used clinically since 1960 and is primarily used for the treatment of 
chronic granulocytic leukaemia. Hydroxyurea selectively inhibits ribonucleotide reductase and 
consequently causes the depletion of dNTP pools, stalling of DNA synthesis and subsequent 
collapsing of replication forks (Bernstein et al., 2010).  
KUO055933 is an inhibitor of the ATM kinase, which has a selectivity at least 100 fold greater 
than any other inhibitors for similar kinases (Li and Yang, 2010).  KUO055933 usage inhibits 
ATM-mediated DNA repair events (Nadkarni et al., 2012).  
PHA-767491 is a dual CDC7/CDK9 inhibitor which has shown cytotoxic activity in a range of 
cancers. One of the drug’s primary features is its ability to downregulate the expression of the 
MCL1 antiapoptotic protein and its cross-reactivity with CDK9. CDC7 is a protein kinase that 
plays an essential role in the initiation of DNA replication and cell cycle progression. CDC7 is 
responsible for the phosphorylation of the minichromosome maintenance 2-7 (MCM2-7) 
complex, which in turn activates its intrinsic DNA helicase activity. This starts the process to 
establish a competent replication fork for semiconservative DNA synthesis. In non-cancerous 
cells, the downregulation of CDC7 by short interfering RNA results in cell cycle progression 
arrest (Natoni et al., 2011). CDK9 is a kinase that forms the catalytic core of positive 
transcription elongation factor b (P-TEFb). This enzyme plays an essential role in the 
stimulation of transcription elongation of most protein coding genes by RNA polymerase II 
(RNAPII) (Kryštof et al., 2012).  
1.3.5 Associated RecQ helicase diseases  
Only three of the RecQ helicases are associated with syndromes that cause premature aging 
and a predisposition to develop cancer. Loss of function of WRN and BLM results in the 
development of autosomal recessive disorders Werner syndrome and Bloom syndrome, 
respectively (Croteau et al., 2012). There are three unrelated autosomal recessive diseases 
that are linked with mutations in RECQL4; Rothmund-Thomson Syndrome (RTS), RAPADILINO 
syndrome and Baller-Gerold syndrome (BGS) (Bernstein et al., 2010, Croteau et al., 2012).  
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RTS is a rare disorder which has seen an increased tendency to develop osteosarcoma in 
patients, shows signs of premature aging and signs of chromosomal instability (Wang et al., 
2003, Kitao et al., 1999). Other characteristics of RTS can be congenital skeletal abnormalities, 
short stature, sparse scalp hair, gastrointestinal disturbances and skin atrophy (Miozzo et al., 
1998, Siitonen et al., 2009). The evaluation of the prominent features of RTS has led to the 
development of two subclasses; type I and type II. RTS type I has mutations in genes that have 
not yet been identified and can be defined by its characteristic poikiloderma. RTS type II 
patients also have poikiloderma but they have documented mutations within RECQL4 which 
seems to be linked to an increase risk of osteosarcoma development (Croteau et al., 2012, 
Siitonen et al., 2009). Most mutations of RECQL4 found in RTS patients are nonsense or 
frameshift mutations that result in a truncated polypeptide (Piard et al., 2015). Somatic cells 
that were harvested from RTS individuals showed genomic instability such as trisomy, 
chromosomal arrangements and aneuploidy (Der Kaloustian et al., 1990).  
RAPADILINO is an acronym that indicates the principal signs of the syndrome: RA for radial ray 
defect, PA for both patellae hypoplasia or aplasia, DI for diarrhoea and dislocated joints, LI for 
little size and NO for long, slender nose and normal intelligence. RAPADILINO patients have 
many similar features to those with RTS such as growth retardation, skeletal malformations, 
and radial defects (Sangrithi et al., 2005, Siitonen et al., 2009). Like RTS patients, RAPADILINO 
patients also have an elevated risk of developing osteosarcomas and lymphomas (Croteau et 
al., 2012). Patients with the BGS phenotypes have shown to have mutations in RECQL4, TWIST 
and FGFR2 genes. BGS can be characterised by craniosynostosis and radial aplasia. Unlike the 
other two RECQL4 associated disorders, BGS patients are not predisposed to the development 
of osteosarcomas (Siitonen et al., 2009).   
1.3.6 Murine models of RTS 
There are several murine models that have been created to mimic RTS, focusing on mutations 
in RECQL4 that map to the helicase region (Bernstein et al., 2010). These mice models are 
useful for studying which symptoms are linked with RTS. Most of the mice died within a two-
week period after being born, but those that survived were smaller in size in comparison to 
wild-type mice. They also displayed other abnormalities such as dry skin, grey hair and also a 
loss of hair reminiscent of premature ageing. These mice, however, did not exhibit some of the 
symptoms RTS patients experience, such as osteosarcomas, poikiloderma and cataracts (Hoki 
et al., 2003). 
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
19 
 
Mann et al. (2005) created another mouse model in their study that mimics RTS through the 
disruption of the helicase domain encoded by exons 9-13 of RECQL4. 16% of these mice died 
within 24 hours of birth but the surviving mice showed an increased prevalence of skeletal 
defects in their limbs. However, these mice showed a normal wild-type life span, unlike RTS 
patients. When these mutant mice were combined with a mutant Apc tumour suppressor 
gene, there was an increased incidence of cancer development (Mann et al., 2005).  
1.4 Aims  
In this study I aim to identify how RECQL4 depletion contributes to the development of 
osteosarcoma in RTS patients. To achieve this aim I will carry out a series of experiments to 
detect chromosomal instabilities, increased sensitivity to genotoxic agents, differentiation 
potential and determine the level of expression of marker genes. Throughout this study I will 
be working with ASC52Telo cells immortalised by hTERT expression.  These results will 
hopefully allow for a better understanding of RECQL4 deficient cells and provide information 
to help identify prevention therapies.  
 
 
2. Materials and Methods 
2.1 Materials  
2.1.1 Cell lines  
ASC52Telo, hTERT immortalised adipose derived MSCs were originally obtained from the 
American Type Culture Collection® at passage 13 for use in previous research studies. These were 
stored in liquid nitrogen and thawed out for use at the beginning of the study. These cells will be 
referred to as “ASC52Telo cells” during this study.  
ASC52Telo cells were osteo-differentiated during a previous PhD research project to use during 
the study. These cells were stored in the liquid nitrogen and thawed out at the beginning of this 
study for use. These cells will be referred to as “OD” cells during this study. 
These “OD” cells were subjected to long term 1.5μM PHA-767491 treatment in order to study the 
effect on OD cells. These cells were thawed out and used during this study and will be referred to 
as “OD+PHA” cells. 
Two shRNA constructs (shRQ-9 and shRQ-10) in the pLK0.1 vector were developed during a 
previous research project. Fourth generation lentiviral particles were generated in 293T cells and 
the viral particles were used to transduce low passage as well as high passage ASC52telo cells by 
Dr Timea Palmai-Pallag. I continued the work with the characterisation of the resulting cell lines. 
2.1.1.1 Media used  
MesenPro RSTM medium was prepared by adding 10mL MesenPro RSTM growth supplement and 
5mL L-Glutamine to 500mL MesenPro RSTM basal medium reduced serum (2%). 
MesenPro RSTM basal medium reduced serum (2%)   Thermo Fisher Scientific 
MesenPro RSTM growth supplement      Thermo Fisher Scientific 
Stem Pro® adipogenesis differentiation kit    Thermo Fisher Scientific 
Stem Pro® osteogenesis differentiation kit    Thermo Fisher Scientific 
Stem Pro® chondrogenesis differentiation kit    Thermo Fisher Scientific 
2.1.2 Plasticware and Glassware 
96 well, standard, F plate (0.290cm2)     Sarstedt  
24 well, standard, F plate (1.820cm2)     Sarstedt 
12 well, standard, F plate (3.650cm2)     Sarstedt 
96 well, microtest plate, F (0290cm2)     Sarstedt 
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T25 flask (canted neck, vented caps)    Sarstedt 
15mL and 50mL conical centrifuge tubes   Sarstedt 
1.5mL microcentrifuge tubes     Sarstedt 
1.5mL cryotubes      Sarstedt 
13mm glass coverslips      Thermo scientific 
Haemocytometer (0.0025mm2/0.1000mm depth)  Sigma Aldrich 
5mL, 10mL and 20mL pipettes     Sarstedt 
20mm Tissue culture dish      CytoOne  
Ministart 0.45μl syringe filter     Sartorius 
2.1.3 Chemicals 
Acetic Acid        Fisher Scientific 
Alizarin Red S       Santa Cruz Biotechnology 
Alcian Blue 8GX       Santa Cruz Biotechnology 
Amersham ECL select western blotting detecting reagent Fisher Scientific 
Bleomycin       Carbosynth 
Bovine Serum Albumin (BSA)     Sigma-Aldrich 
Camptothecin        Sigma Aldrich 
CellTiter 96 aqueous MTS reagent powder   Promega 
Demecolcine       Sigma Aldrich 
Dimethyl Sulfoxide (DMSO)     Insight Biotechnology 
Dithiodibutyric acid (DTT)     Sigma-Aldrich 
Foetal Bovine Serum      Thermo Fisher Scientific (Gibco®) 
Formaldehyde        Cell Signalling Technology® 
Giemsa stain in Giemsa stain phosphate buffer pH 6.8  Gurr®, in StainRite® Wright 
HEPES        Sigma Aldrich 
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Hydroxyurea 98% powder     Sigma-Aldrich 
Isopropanol       Sigma-Aldrich 
KUO055933       Tocris Bioscience 
Methanol        Fisher Scientific  
Mitomycin C       Sigma-Aldrich 
MOPS SDS (20x)      NuPage 
Oil Red O Biological Stain     Fisher Scientific  
Paraformaldehyde       Sigma-Aldrich 
PHA-767491       Sigma-Aldrich 
Phosphate Buffered Saline (PBS) tablets    Fisher Scientific  
Phenazine Methosulfate (PMS)     Sigma-Aldrich  
Quick StartTM Bradford Protein assay    Bio-Rad  
Spectra Multicolor Broad Range Protein Ladder   Thermo Fisher Scientific 
Sodium Dodecyl Sulfate (SDS)     Fisher Scientific (Gibco®) 
Potassium Chloride (KCl)     Melford Laboratories  
Tris/Glycine buffer      Bio-Rad 
Triton X-100       Fisher Scientific (Gibco®) 
Trypan Blue       Sigma-Aldrich 
Trypsin EDTA (10X)      Fisher Scientific 
VECTASHIELD antifade mounting medium    Vector Laboratories 
100% Ethanol        Fisher Scientific 
4X Sodium Dodecyl Sulfate (SDS)    Invitrogen 
2.1.4 Antibodies 
Antibodies are detailed in tables when used during the methods.  
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2.2 Methods 
2.2.1 Routine culture of cells 
All methods carried out in tissue culture were performed in an appropriate laminar flow tissue 
culture hood (Thermo Fisher Scientific) under sterile conditions using 70% ethanol to sterile any 
equipment brought into the hood. Throughout all processes the cells were not allowed to remain 
dry for longer than 30 seconds at a time. All the cells used in this study were routinely cultured in 
6 well, standard, F plates and kept in an incubator set at 5% CO2, 95% relative humidity and 37°C. 
Once ~80% confluency was reached the cells were passaged. Until the cells reached the required 
confluency the media was changed every 2-3 days and the growth monitored using a Nikon 
Eclipse TS100 light microscope. The media was pre-warmed to 37°C before introduction with the 
cells. The cells were passaged by removing the old media, washing with 1mL PBS and then adding 
3 drops of Trypsin using a P100 pipette. The plates were incubated at 5% CO2, 95% relative 
humidity and 37°C with the Trypsin for ~5 minutes until all the cells detached. The plates were 
examined using a light microscope to ensure that all the cells had detached from the plate. 
Following adequate detachment, 1mL of MesenPro RSTM was added to each well and gently 
pipetted up and down to resuspend the cells. Depending on the confluency required during the 
next few days, 0.25-0.5mL of cells were added to a new well on a 6 well, standard, F plate and the 
required volume of prewarmed MesenPro RSTM to make a 1.5mL total volume.    
2.2.2 Cryopreservation of ASC’s  
When confluent, the cells were detached from the culture plates using the method explained in 
section 2.2.1. Once detached the cells were diluted with MesenPro RSTM media and the contents 
transferred into a 15ml conical centrifuge tube. This was centrifuged for 3 minutes at 1500 RPM 
at room temperature using an Eppendorf 5702 R table top centrifuge. The supernatant was 
removed and then the cells resuspended in 250-500μl of MesenPro RSTM that contained 10% 
DMSO and 20% foetal bovine serum. This suspension was transferred to a sterile 1.5mL cryogenic 
tube adequately labelled with the date, cell line, passage number and then transferred to a Mr. 
Frosty Container in the -80°C freezer. 
2.2.3 Recovery of cells 
The cells were removed from the liquid nitrogen storage and kept on dry ice until all equipment 
and reagents were ready for use. Once ready the cells were thawed until almost defrost. The cell 
suspensions were then transferred from the cryogenic tube to a 15mL conical centrifuge tube and 
centrifuged at 1500 RPM for 3 minutes at room temperature. The supernatant was removed, and 
the cells resuspended in 3ml of MesenPro RSTM and centrifuged again to ensure all the DMSO was 
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removed. The supernatant was removed again, and the cells resuspended in 1.5mL media and 
plated on a 6 well, standard, F plate. The plate was then incubated at 5% CO2, 95% relative 
humidity and 37°C. 
2.2.4 Counting cells 
When carrying out experiments that required comparable results between cell lines, it was 
important to plate out equal cell numbers in each well. To count cells the cells were cultured as 
described in section 2.2.1 until the stage where they had detached from the plate. The cells were 
then resuspended in 1mL MesenPro RSTM and 10μL was collected into a 1.5mL microcentrifuge 
tube. 10μL of Trypan blue was also added to the tube. 10μL of this solution was applied to a 
haemocytometer (0.0025mm2/0.1000mm depth) and the number of live cells in each 4x4 grid 
were counted under a light microscope. The use of Trypan blue helps distinguish between live and 
dead cells as only the dead cells take up the blue dye. The total of the four grids were added up, 
double to allow for the Trypan blue dilution and then divided by four to obtain the average 
number of cells per grid. This number is equal to the number of cells in 1μL of suspension, so 
when x103 we know the number of cells per 1mL of suspension. This result can be used to work 
out diluted the suspension needs to be in order to plate the correct number of cells in every well.   
2.2.5 21 day differentiation assay 
The cells were cultured and detached as described in section 2.2.1. 2.5x104 cells of each cell line 
being differentiated were counted and prepared as described in 2.2.4 then each plated into 3 
separate wells on a 24 well, standard, F plate. These were left to settle overnight in the incubator 
at 37°C, 95% humidity and 5% CO2. The following day the complete media was aspirated and each 
of the 3 wells plated for each cell type had MesenPro RSTM replaced with 500μl of either StemPro® 
adipogenesis, osteogenesis or chondrogenesis media. The cells were left to differentiation for 21 
days with the media being changed every 2-3days. Photos of the cells differentiation progress 
were taken after 10 days and at the end of the 21 day period. After 21 days the differentiation 
media was aspirated, and the cells were gently rinsed with 1mL PBS. The PBS was then aspirated, 
and the cells fixed with 500μl of ice cold fixing solution (5mL 0.5M pH 7.4 HEPES, 1.06mL 33% 
paraformaldehyde and 3.94mL deionised water). The plate was incubated for 12 minutes in the 
fridge and following incubation the fixing solution was aspirated and the wells rinsed with 1mL 
PBS for three changes. The cells could now be stored in 1mL fresh PBS in the fridge until ready to 
be stained.  
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2.2.6 Staining of the differentiated cells  
2.2.6.1 Adipocyte staining  
The oil red o stock solution was prepared by weighing out 300mg of oil red o powder and mixing 
this with 99% isopropanol. This stock solution was stable for one year from the date which it was 
prepared. In a fume hood, 3 parts oil red o stock solution was mixed with 2 parts deionised water 
and allowed to sit at room temperature for 10 minutes. This working solution was only stable for 
~2 hours. The working solution was then filtered using a filter syringe into a 50mL conical 
centrifuge tube.  
During the staining the cells were not allowed to remain dry for longer than a period of 30 
seconds at any point. The wells were rinsed gently with sterile water being careful not to disturb 
the monolayer. The water was removed and enough 60% isopropanol to cover the bottom of the 
well was added to each well. This was left to sit for 2-5 minutes. The 60% isopropanol was 
removed and enough of the working oil red o solution was added to completely cover the cells in 
each well. The dish was slowly rotated in order to spread the oil red o evenly over the cells and 
then left to stand for 5 minutes. Once the 5 minutes were up the wells were rinsed with tap water 
until the tap water ran clear. Enough haematoxylin counterstain was then added to each well to 
ensure all the cells were covered and left to stand for 1 minute. The haematoxylin was removed, 
and the plate was rinsed with warm tap water until the water ran clear. Water was left in the 
wells until ready to image using a Nikon Eclipse 80i Fluorescence Microscope in transmitted light 
where any lipids will appear red and nuclei blue.  
2.2.6.2 Chondrocyte staining 
The Alcian blue 8 GX staining solution was prepared by mixing 60mL Ethanol (98-100%) with 40mL 
Acetic Acid (98-100%). 10mg of Alcian Blue 8 GX was dissolved in this solution. The resulting 
working solution was stable for one year from the date it was prepared. 120mL Ethanol (98-100%) 
was mixed with 80mL Acetic Acid (98-100%) to prepare the destaining solution.  
To stain the cells the PBS was removed, and the wells washed with distilled water. Enough Alcian 
staining solution was added to generously cover all the cells as some evaporation can occur. This 
was incubated overnight at room temperature in the dark. Once the incubation period was up the 
Alcian staining solution was removed and the destaining solution was added to each well and left 
to stand for 20 minutes. The destaining solution was removed and PBS added to each well. The 
cells could then be imaged on the phase microscope where any cartilage is an intense dark-blue 
and other tissue is at most a faint blue.  
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2.2.6.3 Osteocyte staining 
The Alizarin Red S staining solution was prepared by dissolving 2g Alizarin Red S in 100mL distilled 
water, mixing it and then adjusting the pH to 4.1-4.3 with 0.1% NH4OH. This solution was then 
filtered and stored in the dark.  
To stain the cells the PBS was removed, and enough Alizarin Red S staining solution added to each 
well to cover the monolayer. This was incubated at room temperature in the dark for 3-5 hours. 
The Alizarin Red S staining solution was removed, and the monolayer washed four times with 
distilled water. The water was removed, PBS added to each well and the cells imaged. 
Undifferentiated MSCs were slightly reddish whereas MSC derived osteoblasts were bright 
orange-red.  
2.2.7 Immunofluorescent staining 
2.2.7.1 Preparation of the cells for staining 
13mm diameter round cover slips were autoclaved and then sterilised in 70% ethanol to ensure 
they were completely sterile. One cover slip was then added to each well of a 24 well, standard, F, 
culture plate, rinsed with PBS and left to dry to ensure the removal of any residual ethanol. 3x104 
cells of each cell line being stained were seeded per well in MesenPro RSTM at a total of 1mL per 
well as described in sections 2.2.1 and 2.2.4. The plates were incubated at 5% CO2, 95% relative 
humidity and 37°C until ~80% confluency was achieved. Until then the media was changed every 
2-3 days, taking care not to disturb the monolayer. Once confluency was reached, the media was 
aspirated, and the wells rinsed with 1mL PBS. The PBS was then aspirated at 0.5mL of ice cold 
fixing solution (5mL 0.5M pH 7.4 HEPES, 1.06mL 33% paraformaldehyde and 3.94mL deionised 
water) was added to each well and incubated for 12 minutes. The fixing solution was aspirated, 
and the wells rinsed with 0.5mL PBS for three changes. 0.5mL of permeabilisation solution (10μl 
Triton X-100, 9.99mL PBS) was added to each well and incubated on ice for 20 minutes. This 
solution was then aspirated, and the cells were rinsed with 0.5mL PBS for a further 3-5 changes 
whilst gently rocking the plate. 0.5mL of blocking solution (10% Foetal Bovine Serum, 0.1% Triton 
X-100 in PBS) was added to each well and the plate incubated at 37°C for one hour. This solution 
was aspirated, and the cells stored in 0.5mL PBS until ready to be stained.  
2.2.7.2 Staining of the cover slips: Ki67, RUNX2, Osterix and 53BP1. 
The cells were prepared as explained in 2.2.7.1. Enough of the primary antibody for each stain 
was prepared to the correct dilution and volume to allow for 20μl per cover slip.  
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Table 2. Primary antibodies used in Immunofluorescent staining. 
Stain Company Product code Animal Dilution 
Ki67 Abcam Ab15580-100 Rabbit 1:200 
Osterix R&D systems MAB7547 Mouse 1:200 
53BP1 Bethyl laboratories A300-272A Rabbit 1:500 
RUNX2 Santa cruz SC10758 Rabbit 1:200 
 
20μl of the primary was dropped onto a clean glass slide and the cover slip removed from the 24 
well plate, standard, F and placed cell side down onto the antibody. The edges of the coverslip 
were then fixed with Fixogum (Marabu) to retain moisture. Once the Fixogum had dried, the slide 
was placed into a clean petri dish with a damp piece of tissue and sealed with parafilm. These 
petri dishes were incubated overnight at 4°C. The following day, the Fixogum was removed from 
the slides and the cover slips replaced, cell side up, back into the 24 well, Standard, F, culture 
plate. The cover slips were then washed with 0.5mL PBS for 5 changes whilst rocking, each for a 
period of 5 minutes. A final wash was done with deionised water to remove any residual salt from 
the PBS. The secondary antibodies were then prepared according to table 3.  
Table 3. Secondary antibodies used in fluorescent staining. 
Stain Company Alexa Fluor  Cat. No. Animal Dilution 
Ki67, RUNX2, 
53BP1 
ThermoFisher 
Scientific 
AF488 A11055 Donkey anti-
rabbit 
1:800 
Osterix ThermoFisher 
Scientific 
AF555 A21422 Goat anti- 
mouse 
1:800 
 
150μl of the diluted secondary antibody was added to each well. The plate was sealed with 
parafilm and incubated in the dark at 5% CO2, 95% relative humidity and 37°C for one hour. After 
an hour the antibody was aspirated, and the coverslips were washed with 0.5mL PBS for 5 
changes and a final wash was done with deionised water. The coverslips were then removed and 
placed cell side up on Whatman® 3M filter paper to air dry. It is important that they remain in the 
dark whilst air drying. 10μl of VECTASHIELD antifade mounting medium with DAPI was applied to 
each cover slip. Each coverslip was mounted onto a clean glass slide. Light pressure was applied to 
the coverslips using Whatman® 3M filter paper to remove any excess VECTASHIELD. The slides 
were then sealed with clear nail varnish and stored at 4°C until ready to be imaged using the Leica 
confocal microscope.  
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2.2.7 Western blotting 
Prior to starting the western blot, the cells should be counted, as described in 2.2.4, and seeded 
into a standard 96 well, standard, F plate with a cell number of 1x104.  The cells were incubated 
overnight to ensure they’ve settled. 
2.2.7.1 Lysing the cell 
Reagents used: 
2x lysis solution: 25mM Tris-HCl (pH7.6) + 150mM NaCl + 1% NP-40 + 1% sodium-deoxycholate + 
0.1% SDS. 
Protein lysis buffer stock: 5ml 2x lysis stock solution + 3ml 18MΩ H20 + 500μl 5mM NaPPi + 100μl 
10 mM NaF. 
Protease inhibitor: 1 mini complete tablet + 1ml 18MΩ H20 (7x solution). 
Western blotting lysis buffer: 420 μl Protein lysis buffer stock + 71.4 μl protease inhibitor cocktail.  
PBS: 1 phosphate buffered saline tablet per 100 ml 18MΩ H20 (1x).  
To lyse the cells ready for western blotting the media was aspirated from the wells and then the 
wells were rinsed twice in0 .5mL PBS. The PBS was removed, replaced with 30μl of lysis buffer 
containing protease inhibitor and then left the plate to stand on ice for three minutes. The lysates 
were then collected into 1.5mL microcentrifuge tubes and kept on ice whilst processing the rest 
of the samples. The samples were then sonicated four times for three seconds bursts each time 
using Soniprep 150 Ultrasonic Disinegrator at full power. These lysates were then centrifuged at 
13,000 RPM, 4°C for 20 minutes.  
2.2.7.2 Protein content quantification 
The protein concentration of each sample was quantified using Quick StartTM Bradford Protein 
Assay.  5μl of each of the bovine serum albumin protein standards of known concentrations were 
added to a fresh 96 well, microtes plate, F (BSA: 0.1 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1.0 mg/ml, 
1.5 mg/ml, 2.0 mg/ml) including a blank of lysis buffer. Each of the samples were diluted 1:5 in 
H20 and 5μl of each sample was added to the 96 well, microtest, F plate. 250μl of Quick StartTM 
Bradford Reagent was added to each well and the plate incubated for 5 minutes in the dark. Using 
SoftMax Pro software, the plate could be read at an absorbance of 595nm using the Hidex 
Chameleon plate reader and SoftMax Pro 5.2 software. and the results used to calculate the 
appropriate dilutions for the western; the sample with the lowest protein sample was set as 100% 
and the high concentrations were diluted in lysis buffer in comparison to this concentration, 
ensuring a maximum loading volume of 20μl.  
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2.2.7.3 Running samples 
5μl of 4X Sodium Dodecyl Sulfate (SDS) Sample buffer supplemented with DTT was added to each 
of the samples in 200μl PCR tubes and then denatured at 98°C for 5 minutes using the C100 
TouchTM Thermal Cycler (BioRad). The samples were left on ice for two minutes and then 
centrifuged to reduce any condensation.   
2.2.7.3.1 10 well precast gradient polyacrylamide gels (Novex NuPage) 
These were running in CriterionTM running tanks (BioRad) using 500ml MOPS running buffer (25ml 
MOPS SDS (20X) + 475ml 18MΩ H20). A maximum of 20μl was loaded per well and 7μl of Spectra 
Multicolor Broad Range Protein Ladder was loaded either side of the sample. The gel was run at 
150V for ~1.5hours.  
2.2.7.3.2 18 well precast gradient polyacrylamide gels 
These were also running in CriterionTM running tanks (BioRad) using 500ml 1xTris-Glycine-SDS 
running buffer (30g Tris base, 144g Glycine 10g SDS + 1 litre H20).  A maximum of 30μl was loaded 
per well and 7μl of Spectra Multicolor Broad Range Protein Ladder was loaded either side of the 
sample. The gel was run at 120V for ~1 hour or 200#v for ~45 minutes.  
2.2.7.4 Blotting  
Once the gel had finished running the gel was transferred to Hybond ECL nitrocellulose 
membrane a blotting chamber filled with transfer buffer 1x Tris Glycine with 10% MetOH (100ml 
10x Tris-Glycine buffer + 700ml H20 + 200ml MetOH). Run at 100V for 50 minutes. 
2.2.7.5 Blocking, incubation with antibodies and imaging 
The membrane was blocked in the appropriate solution; either 5% milk in PBS-Tween (0.1%) or 
5% BSA in PBS-Tween (0.1%) for 30 minutes on a rocker. Primary antibodies were diluted using 
the same blocking buffer to the appropriate dilution.  
Table 4. Primary antibodies used in Western Btotting. 
Band Company Product code Animal Dilution 
RECQL4 Cell signalling 28145 Rabbit 1:500 in BSA 
Tubulin alpha Bio-Rad MCA78G Mouse 1:104 in milk 
 
The membrane was sealed in plastic pockets along with the diluted primary antibodies and 
incubated rotating at 4°C overnight. The membrane was then removed from the plastic pocket 
and washed in an excess of PBS-0.1% Tween-20 buffer for 10 minutes whilst rocking. This step 
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was repeated three times. Secondary antibodies were diluted in the same blocking buffer to the 
appropriate dilution and incubated with the membrane for 1 hour at room temperature.  
Table 5. Secondary antibodies used in western blotting. 
Band Company Product code Animal Dilution 
RECQL4 Promega F00108 Anti-rabbit IgG 
(FC) AP conj. 
1:5000 in BSA 
Tubulin Promega F00109 Anti-mouse IgG 
(H+L) AP conj. 
1:10000 in milk 
 
After an hour the membrane was washed in PBS-0.1% Tween-20 buffer for 10 minutes whilst 
rocking. This was repeated four times. Amersham ECL Select Wester Blotting Detection Reagent 
was used with a 1:1 ratio of the luminol and peroxide solutions. The membranes were incubated 
in the dark and then developed using x50 Autoradiography film (GE Healthcare Amersham).  
2.2.8 Growth assay 
1.5x103 cells of each cell line being analysed were seeded into 96 well, standard, tissue culture 
plates as described in sections 2.2.1 and 2.2.4. One plate was analysed each day for 7 days using 
MTS/PMS solution to analyse the number of metabolically active cells. Both the MTS solution and 
the Phenazine methosulfate (PMS) solution were made up as per the manufacturer’s instructions 
and aliquoted before needed then stored at -20°C. Immediately before use the solutions were 
thawed and 50μl of PMS solution was added to 1.0ml of MTS solution (MTS:PMA 1:20). 20μl of 
the combined MTS/PMS solution was pipetted into each well of the 96 well, standard, F plate. The 
plate was incubated for 1-4 hours at 37°C in a 95% humidified and 5% CO2 atmosphere. The 
absorbance was read at 490nm using the Hidex Chameleon plate reader. This was repeated every 
24hours for 7 days.  
2.2.9 Drug sensitivity assay 
To determine the sensitivity of each cell line to a variety of drugs, the cells were grown and 2x103 
were seeded into 96 well, standard, F, tissue culture plates as described in sections 2.2.1 and 
2.2.4. The cells were left to settle overnight in 100μl of complete MesenPro RSTM. The following 
day the MesenPro RSTM was removed and were the treated with different concentrations of the 
chosen drug over a 6 day period. The drugs were diluted in MesenPro RSTM. The media containing 
the drug was changed after 2-3 days. After 6 days an MTS assay was carried out on each plate as 
described in section 2.2.8.  
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2.2.10 Chromosome preparation 
3x105 cells were seeded in 90cm petri dishes in 8mL of complete MesenPro RSTM and left to grow 
until around 70% confluent as described in 2.2.1 and 2.2.4. Once the appropriate confluency was 
reached, 80μl of 10μg/mL Demecolcine was added to each petri dish to arrest the cells in 
metaphase. The cells were incubated for 8 hours at 95% humidity, 37°C and 5% C02. During this 
time 75mM Potassium Chloride and Caranoy’s fixative (Methanol and Glacial Acetic acid at a ratio 
of 3:1) was prepared ready for use in the following steps. After 8 hours the media was removed 
and collected into a 15mL conical centrifuge tube. The cells were then rinsed in 3mL pre-warmed 
PBS which was subsequently removed and put into the same conical centrifuge tube. 1mL of 
trypsin was added to each petri dish and incubated until the cells detached. The cells were 
collected from the petri dish using the media collected in the 15mL conical centrifuge tube. The 
plate was then rinsed one final time with PBS to collect any remaining cells and also put in the 
same 15mL conical centrifuge tube. Each conical centrifuge tube was centrifuged at 1.0K RPM for 
5 minutes. Once centrifuged the supernatant was carefully removed and the cells washed with 
PBS. Each time a new solution was added the 15mL conical centrifuge tube was flicked to agitate 
the cells and re-suspend them. The tubes were centrifuged once more at 1.0K RPM for 5 minutes. 
The supernatant was removed once again and 7mL of warm 75mM Potassium Chloride solution 
was added dropwise to each tube to hypotonise cells. The tubes were incubated for 8 minutes in 
a 37°C water bath and then centrifuged at 1.0K RPM for 5 minutes. The supernatant was removed 
and 7mL of Caranoy’s fixative mixed with PBS (1:1 ratio) was added dropwise to each tube. The 
tubes were further centrifuged at 1.2K RPM for 5 minutes. The cells were then fixed by the 
dropwise addition of 7mL Caranoy’s fixative. The tubes were centrifuged at 1.2K RPM for 5 
minutes. This addition of Caranoy’s fixative was repeated once more and after a final centrifuge 
most of the supernatant was removed leaving only 0.5mL. The cells were re-suspended and 
stored at -20°C overnight. The following day the fixed cells were dropped onto slides and left to sit 
overnight.  
2.2.10.1 Giemsa staining 
The slides were rinsed for 5 minutes in PBS using a Coplin jar. These slides were then transferred 
into a Coplin jar containing 10% Giemsa staining solution (Gurr®, in StainRite® Wright-Giemsa 
stain phosphate buffer pH 6.8) for ~1 hour. The slides were then transferred to a final Coplin jar 
and washed three times with distilled water. The slides could then be imaged under a Nikon 
Eclipse 80i Fluorescence Microscope in transmitted light. Images were taken of the chromosomes 
and the number of chromosomes present were counted. 
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3 Results 
The following section presents the data and images collected from the experiments carried out 
during this project.  
3.1  Verification of RECQL4 depletion by western blot 
In order to study the effect of RECQL4 depletion in ASC cells, two shRNA constructs (shRQ-9 and 
shRQ-10) were previously built in the pLKO.1 vector in our laboratory as part of a PhD project. 
Fourth generation lentiviral particles were generated in 293T cells and the viral particles were 
used to transduce low passage as well as high passage ASC52telo cells by Dr Timea Palmai-Pallag. I 
continued the work with the characterisation of the resulting cell lines. 
A western blot was performed to determine whether RECQL4 was adequately depleted by the 
Lentiviral shRNA construct. The RECQL4 protein is 150kDa in size and a band at this mark is only 
expected to be seen for P14 pLKO.1 and p44 pLKO.1 
Figure 7. Western blot to verify depletion of RECQL4 in the ASC52telo clones. A) Lower and higher passage 
knockdowns and their pLKO.1 controls probed for RECQL4 protein levels. B) Tubulin controls of each sample to control 
equal loading.  
 
A clear western blot was not obtained, and a high background can be seen. However, the band for 
P44 shRQ-9 and P44 shRQ-10 is a lot weaker in intensity than for any of the other cell lines. The 
control samples have a visibly stronger band. β-Tubulin was used as loading control to give a 
visualisation of whether equal amounts of protein from each sample were loaded.   
A 
B 
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
33 
 
3.2  Assaying Differentiation capability 
In order to assess if suppression of RECQL4 expression impacts differentiation capability of our 
adipose-derived stem cells their trilineage differentiation capacity was tested with standard 
methods. 
 
 
 
 
 
 
 
 
 
  
Figure 8. Trilineage potential of ASC52telo cells. Differentiation capability of ASC52telo cells into adipocytes, osteocytes 
and chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 
10 days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 
21 days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte 
differentiation stained with Alcian Blue after 21 days (x40). 
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Figure 9. Trilineage potential of P14 pLK0.1. Differentiation capability of P14 pLK0.1 cells into adipocytes, osteocytes 
and chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 
10 days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 
21 days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte 
differentiation stained with Alcian Blue after 21 days (x40). 
 
A 
A B C 
D E F 
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
35 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 10. Trilineage potential of P14 shRQ-9. Differentiation capability of P14 shRQ-9 into adipocytes, osteocytes and 
chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 10 
days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 21 
days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte differentiation 
stained with Alcian Blue after 21 days (x40). 
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Figure 11. Trilineage potential of P14 shRQ-10. Differentiation capability of P14 shRQ-10 into adipocytes, osteocytes and 
chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 10 
days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 21 
days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte differentiation 
stained with Alcian Blue after 21 days (x40). 
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Figure 12. Trilineage potential of P44 pLK0.1. Differentiation capability of P44 pLK0.1 into adipocytes, osteocytes and 
chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 10 
days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 21 
days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte differentiation 
stained with Alcian Blue after 21 days (x40). 
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Figure 13. Trilineage potential of P44 shRQ-9. Differentiation capability of P44 shRQ-9 into adipocytes, osteocytes and 
chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation after 10 
days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red O after 21 
days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte differentiation 
stained with Alcian Blue after 21 days (x40). 
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The ASC52Telo cells, RECQL4 knockdowns and their controls were treated for 21 days with 
adipogenesis, osteogenesis and chondrogenesis media, to establish whether all the cell lines still 
have the trilineage differentiation potential found in normal MSCs. All cell lines differentiated into 
adipocytes, shown by the presence of lipid vacuoles, and osteoblasts, shown by the presence of 
Alizarin red stained calcified extracellular matrix, but we had difficulties with chondrogenic 
differentiation due to the loss of cells and detachment of the monolayer. The higher passage 
PLK0.1 and shRQ-9 cells appear to have a decreased adipocyte differentiation in comparison to 
the lower passage cells.  
Figure 14. Trilineage potential of P44 shRQ-10. Differentiation capability of P44 shRQ-10 into adipocytes, osteocytes 
and chondrocytes after 10 and 21 days. A) adipocyte differentiation after 10 days (x40), B) osteocyte differentiation 
after 10 days (x40), C) chondrocyte differentiation after 10 days (x40), D) adipocyte differentiation stained with oil red 
O after 21 days (x40), E) osteocyte differentiation stained with Alizarin Red after 21 days (x100) and F) chondrocyte 
differentiation stained with Alcian Blue after 21 days (x40). 
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As the first step to characterise the cultures that were recovered from long term osteogenic 
differentiation, we wanted to show if this culture still contains cells that are capable to 
differentiated into directions other than osteoblasts. OD and OD+PHA cells were treated for 21 
days with adipogenesis media to see if any differentiation occurs. Both cell lines show the 
presence of lipid vacuoles, with the PHA-767491 treated OD cells displaying a lower number in 
comparison to the untreated OD cells.  However, their overall morphology and the extent of 
adipogenic differentiation is different to what was observed using ASC52telo cells. 
Figure 15. Adipogenesis potential of OD and OD+PHA cell lines. OD and OD+PHA cells after 
10 days and 21 days culturing with adipogenesis media. A) OD cells after 10 days culturing in 
adipogenesis media (x40), B) OD+PHA cells after 10 days culturing in adipogenesis media 
(x40), C) OD cells after 21 days culturing in adipogenesis media (x40), D) OD+PHA cells after 
21 days culturing in adipogenesis media (x40). 
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3.3  Growth assay 
We also wanted to assess whether there was a difference in the growth characteristics of cells in 
which RECQL4 was depleted, or replication initiation was disturbed during osteogenic 
differentiation. Seven plates were set up for each cell line and an MTT assay carried out on a plate 
each day. This allowed us to plot the growth of the cell lines over a period of 7 days.  
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Figure 16. Growth curves of all the knockdowns, their controls, OD cells and OD+PHA cells. 
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No significant difference was observed between the cells in which RECQL4 was knocked down and 
their controls. Cells that were recovered from osteoblastic differentiation (OD cells) have the 
quickest cell proliferation rate and for the first four days, the OD cells treated with PHA-767491, 
to interfere with replication initiation, proliferate at half the rate of the untreated OD cells. 
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3.4  Immunofluorescence staining 
Immunofluorescence staining was carried out on the knockdowns, OD cells and OD+PHA cells to 
identify any differences in 53BP1, Ki67, RUNX2 and Osterix expression.  
3.4.1 53BP1 staining 
53BP1 is essential in maintaining genome stability and is an important mediator of DNA damage 
checkpoint. Abnormal expressions of 53BP1 have been linked with tumour prevalence and 
development (Bi et al., 2015). 
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DAPI 53BP1 and DAPI 53BP1 
Figure 17.  Immunofluorescence images of each cell line stained with DAPi (blue) and 
53BP1 (green). 
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The results show a lower average foci number in P44 shRQ-9 cells particularly in comparison to 
the rest, and P14 PLK0.1 and P44 shRQ-10 show a higher count. There are no significant 
differences between the cell lines.  
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Figure 18. The average foci count of each cell line when stained to show 53BP1 expression. The confocal images 
were analysed using cell profiler which provided the number of foci counted per cell. The average could then be 
calculated. 
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3.4.2 Ki67 staining 
Ki67 protein expression is associated with cell proliferation. It can be detected during all active 
phases of the cell cycle, but is absent in G0 phase (resting cells) (Scholzen and Gerdes, 2000). 
 
 
 
 
 
P14 pLK0.1 
OD 
OD+PHA 
Ki67 and DAPI DAPI Ki67 
P14 shRQ-10 
P14 shRQ-9 
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
47 
 
  
DAPI Ki67 and DAPI Ki67 
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Figure 19. Immunofluorescence images of each cell line stained with DAPI (blue) and 
Ki67 (green). 
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Figure 20. The Ki67 staining intensity of each cell line group into dim, borderline and strong intensities. The confocal 
images were analysed using cell profiler which provided the number of foci counted per cell. The average could then be 
calculated. 
 
Intensity of the KI67 signal was quantified with CellProfiler and cells were categorised as ‘strong’ 
and actively proliferating, and ‘dim’ as resting cells. A third category was established and 
characterised by a small number of cells which cannot be convincingly put in either of the two 
categories; these cells are likely in the process of exiting cycling. At least 60% of the intensity 
results for each cell line are in the strong category, suggesting all the cell lines contain a 
considerable proportion of proliferating cells. The P14 shRQ-10 cells have the lowest proportion 
of intensities in the strong category out of all the cell lines, suggesting that this cell line is the least 
actively proliferating.  
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3.4.3 RUNX2 and Osterix staining 
RUNX2 and Osterix are transcription factors that play an essential role in bone formation and 
osteoblast differentiation (Martin et al., 2011). RUNX2 is expressed in mesenchymal stem cells 
and during early osteoblast differentiation (Martin et al., 2011), while Osterix expression is 
characteristic to osteoblasts.   
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Figure 22. Immunofluorescence staining of each cell line with DAPI (blue), RUNX2 (green) 
and Osterix (red). 
Figure 21. A graph to show the average foci count of each cell line when stained to show RUNX2 expression. The 
confocal images were analysed using cell profiler which provided the number of foci counted per cell. The average 
could then be calculated. 
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The RUNX2 average foci count results show a higher count in the p44 knockdowns than the rest of 
the cell lines. The OD cells have the second lowest count which is expected as these cells contain a 
large proportion of fully differentiated osteoblasts, and a population of undifferentiated MSCs 
that are still RUNX2 positive. The Osterix foci count shows results that we would expect to see 
from these cell lines. The average foci count is much higher in the two osteo-differentiated cell 
lines compared to the six knockdowns. The osteo-differentiated cells treated with PHA-767491 
display a lower Osterix expression, suggesting a slower osteoblast differentiation rate. 
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Figure 23. A graph to show the average foci count of each cell line when stained to show Osterix expression. The 
confocal images were analysed using cell profiler which provided the number of foci counted per cell. The average 
could then be calculated. 
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3.5  Drug sensitivity assays 
The literature reports contradictory results of sensitivity of cells mutated in RECQL4. We wanted 
to know how depletion of RECQL4 in ASC cells affects their sensitivity to drugs that induce DNA 
damage. 
 
 
 
 
 
 
 
 
Figure 24. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells, OD cells, OD+PHA 
cells+ (PHA present) and OD+PHA cells- (PHA not present) with Hydroxy Urea for a period of 7 days. Logarithmic scale, 
base 10. 
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Figure 25. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells and OD cells 
with KUO055933 for a period of 7 days. Logarithmic scale, base 5. 
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Figure 26. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells, OD cells, OD+PHA+ 
cells (PHA present) and OD+PHA- cells (PHA not present) with Camptothecin for a period of 7 days. Logarithmic scale, 
base 10. 
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Figure 27. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells, OD cells,) and 
OD+PHA- cells (PHA not present) with Mitomycin C for a period of 7 days. Logarithmic scale, base 10. 
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Figure 28. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells and OD cells 
with PHA-767491 for a period of 7 days. Logarithmic scale, base 2. 
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Figure 29. Survival assays for the treatment of the knockdowns, their controls, ASC52Telo cells and OD cells 
with Bleomycin for a period of 7 days. Logarithmic scale, base 10. 
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Survival assays were carried out on all of the cell lines testing for sensitivity when treated with 
Bleomycin, Mitomycin C, PHA-767491, Camptothecin, KU0055933 and Hydroxy urea. The cells 
were treated for a period of seven days with each drug and an MTT assay carried out at the end of 
the seven days to test the number of viable cells left. These results are plotted on graphs to show 
the decrease in viability as drug concentration increases (see figures 24-29). The assays are 
plotted on a logarithmic scale to better the spread of the results. The results show no significant 
difference in sensitivity between the controls and the RECQL4 deficient cells. However, we can 
see from some of the sensitivity assays that p14 shRQ-10 and p44 shRQ-10 appear to be less 
sensitive in the mid-range concentrations in comparison to the control ASC52Telo cells and OD 
cells.  
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3.6  Evaluation of chromosomal instability 
Mutations of RECQL4 and interference with replication initiation may cause chromosomal 
instabilities (Maire et al., 2009). Chromosomes were prepared from each cell line and analysed to 
identify any chromosome alterations.  
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Figure 30. Preparation and count of chromosomes in ASC52Telo cells. ~35 sets of chromosomes were imaged, counted 
and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 31. Preparation and count of chromosomes in OD cells. ~35 sets of chromosomes were imaged, counted and 
analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of chromosomes 
in each cell counted. 
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Figure 32. Preparation and count of chromosomes in OD+PHA cells. ~35 sets of chromosomes were imaged, counted 
and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 33. Preparation and count of chromosomes in P14 pLK0.1 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 34. Preparation and count of chromosomes in P14 shRQ-9 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 35. Preparation and count of chromosomes in P14 shRQ-10 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 36. Preparation and count of chromosomes in P44 pLK0.1 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 37. Preparation and count of chromosomes in P44 shRQ-9 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Figure 38. Preparation and count of chromosomes in P44 shRQ-10 cells. ~35 sets of chromosomes were imaged, 
counted and analysed for any alterations. A) giemsa stained chromosomes (x100), B) a graph showing the number of 
chromosomes in each cell counted. 
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Cells were arrested in metaphase and chromosomes were prepared from all of the cell lines and 
then dropped onto glass slides. These slides were then stained with Giemsa and ~35 metaphase 
nuclei were imaged. The chromosomes were counted for each cell that was imaged and analysed 
to identify any signs of chromosomal alterations. None of the cells lines show any signs of 
structural chromosomal alterations that were observable with this technique. The chromosome 
counts show a modal count of 46, which is the normal number of chromosomes expected to be 
seen. Each cell line has cells that display aneuploidy, missing or gaining only one or two 
chromosomes. Importantly however, cells with a modal chromosome number of 92, (tetraploid 
cells) and cells with an increased degree of aneuploidy can be seen in the OD+PHA, P44 shRQ-9 
and P44 shRQ-10 cell lines.  
  
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
69 
 
4. Discussion 
This study set out to identify how RECQL4 depletion in ASC52Telo cells contributes to the 
development of osteosarcoma in RTS patients using long term in vitro culturing of hTert 
immortalised ASC52Telo cells.  
Verification of RECQL4 knockdown 
The tubulin control confirms that a comparable amount of each protein sample was loaded. 
Although bands are seen at 150kDa on the western as expected, there are also non-specific bands 
present at other molecular weights on the western. The band at around 100kDa is likely a 
degradation product. The western blot results suggest the knockdown is working at a good 
efficiency in the higher passage clones, both shRQ-9 and shRQ-10, whereas the knockdown in the 
lower passage clones is less convincing. 
The RECQL4 antibody used in this experiment has caused difficulties in the past due to its quick 
loss of activity when in storage. It has also proven sensitive to the blocking agent used and so 
after some experimentation BSA was identified as the most efficient blocking agent. The levels of 
RECQL4 expression is also cell cycle-dependent and so cells that are slow cycling or unhappy show 
very low expression. When loading the samples, they are normalised for total protein 
concentration and as ASC cells are very large and there is a possibility of under loading the gel for 
the detection of RECQL4; a nuclear protein. To try and solve this issue of under loading the cell 
extracts were fractionated to enrich any nuclear proteins present. Unfortunately, this extra 
process did not produce any results that were more successful. Nevertheless, the western results 
confidently show that the knockdown of RECQL4 has worked at least in high passage cells and 
perhaps in low passage cells with shRQ-9. 
Differentiation capability of RECQL4 containing ASCs and RECQL4 deficient 
ASCs.  
Adipogenesis and osteogenesis can be seen in all the cell lines to some degree. A study by Ng et 
al. (2015) showed a decrease in osteogenic differentiation in conditional Recql4 mutant mice, 
which supports the low bone mass and short stature symptoms seen in RTS patients. Our RECQL4 
deficient cells lines appeared to carry out osteogenic differentiation equally as well as the control 
cell lines. The higher passage cell lines seemed to show a lower number of cells that successfully 
differentiated into adipocytes as a lower number of vacuoles are present both at day 10 and day 
21. Higher passage numbers can sometimes see alterations in the ability of the cells to 
differentiate and proliferate efficiently which could explain the difference in our results for each 
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cell line induced to carry out adipogenesis. Our chondrogenic differentiation does not show the 
results we were expecting to see, as there is a distinct lack of cells growing on the coverslip. The 
sparse number of cells present may be due a faster rate of proliferation that caused the cells to 
become over-confluent and lift off the cover slip. This results in the cells being washed away 
during a media change. This occurred during every repeat of this experiment.   
The OD and OD+PHA cells were only treated with adipogenesis media to see if the recovered 
populations contain cells with mesenchymal stem cell characteristics, or whether they are 
differentiated osteoblasts. The results suggest that some cells may be able to differentiate into 
adipocytes. However, given that the number of cells that differentiated to adipocytes was 
considerably lower than in parallel control cultures, it suggests that these cultures contain a high 
percentage of committed osteogenic cells. The presence of PHA-767491 doesn’t seem to affect 
the differentiation capability of these cultures.  
Expression of marker genes: Ki67, RUNX2, Osterix and 53BP1 
The differentiation capability results of the OD and OD+PHA cells is further supported through the 
immunostaining for the expression of marker genes. Osterix and RUNX2 are transcription factors 
involved in bone formation and osteoblast differentiation (Martin et al., 2011). Osterix is a more 
accurate marker of osteoblast differentiation as RUNX2 is expressed in MSCs, as well as early 
osteoblasts (Zou et al.). The RUNX2 results show no significant difference whereas our average 
Osterix foci number is much higher in OD and OD+PHA cells, confirming that there is a higher 
percentage of committed osteogenic cells. Lu et al. (2008) reported that when quantitative 
reverse transcription-PCR analysis of RUNX2 in osteosarcoma patient’s samples was carried out, 
overexpression of RUNX2 was seen. Our results show that when treated with PHA-767491 a 
higher level of RUNX2 expression was seen, suggesting that PHA-767491 treatment may induce 
transformation and osteosarcoma in these treated cultures. A link could be possible in p44 pLK0.1 
and p44 shRQ-9 cells between a high RUNX2 expression and a reduced capability in 
differentiating.  
53BP1 is an important mediator of DNA damage check points and abnormal quantities can be 
linked with tumour development (Bi et al., 2015). It is a key regulator of DSB repair pathway 
choice and promotes NHEJ during G1 by antagonising DNA end-resection (Panier and Boulton, 
2013). A study by Singh et al. (2010) showed that when exposed to gamma-irradiation, RECQL4 
deficient fibroblasts displayed an increased number of 53BP1 foci. This suggested that defects in 
efficient DSB repair were present in the RECQL4 deficient fibroblasts. Our results show no 
statistically significant differences between the levels of 53BP1 expression in each cell line. 
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Contrary to the results found by Singh et al. (2010), the p14 shRQ-9, p14 shRQ-10 and p44 shRQ-9 
cells show a lower average foci count in comparison to the other cell lines. These results could 
suggest that there is no abnormal DNA damage to any of the cell lines.  
Ki67 protein expression is associated with cell proliferation (Scholzen and Gerdes, 2000). Studies 
of breast cancer patients have shown that a high level of Ki67 expression is associated with a 
worse prognosis (Inwald et al., 2013). This suggests that any development of osteosarcoma will 
result in an increased expression of Ki67 being present. Our results show no significant differences 
in the expression of Ki67 between the knockdowns and the controls.  
Differences in growth  
RECQL4 plays an important role in DNA replication initiation and so without this gene it is 
assumed that the efficiency of cell proliferation would be decreased as DNA replication would 
occur at a reduced rate. _ENREF_76Sangrithi et al. (2005) obtained evidence that RECQL4 
depletion results in cell proliferation failure. The results from this study do not complement this 
evidence as no significant difference can be seen between the RECQL4 deficient cells and the 
controls. This is, although unexpected, not inexplicable. There might be some residual RECQL4 
expression in these clones, as suggested by Figure 7. It is not uncommon to achieve only around 
95% knockdown with siRNA / shRNA, and this residual activity can be sufficient enough to carry 
out some functions meaning the cells that are more sensitive to expression levels might be 
affected (Fakhr et al., 2016). Patient-derived RECQL4 mutant cell lines can also display different 
degrees of activity, which may explain the differences they show in proliferation capacity. Full 
knockout of Recql4 in the mouse is embryonic lethal, other mouse mutant alleles are 
hypomorphic with residual expression that retains some activity of the protein (Xu and Liu, 2009). 
Sensitivity to genotoxic stress 
There are a number of studies available that provide data and information on the sensitivity of 
RTS cells to different genotoxic agents, and the data that is available is contradictory. These 
inconsistent findings could indicate genetic heterogeneity in RTS (Jin et al., 2008). As RECQL4 
plays a key role in DNA replication initiation, sensitivity is expected to be seen in RECQL4 deficient 
cells when treated with DNA damaging agents that inhibit replication. This is because stalled 
replication forks can be rescued by the firing of dormant origins (Petermann et al., 2010), and if 
this firing is inhibited it results in sensitivity to replication inhibition in general. To test if our 
RECQL4 deficient cells were more sensitive in comparison to their controls, we treated them for a 
seven day period with Camptothecin, Mitomycin C, Hydroxy Urea, PHA-767491, Bleomycin and 
KU0055933 and then evaluated the cytotoxic effect using an MTT assay. Mitomycin C and Hydroxy 
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Urea both cause replication fork arrest directly as Mitomycin C creates DNA inter-strand crosslinks 
and Hydroxy Urea inhibits ribonucleotide reductase, which depletes the dNTP pool. Camptothecin 
is an inhibitor of DNA topoisomerase I; it arrests TOPO1 in its transient state when the single-
stranded break is created by the enzyme and it induces collapse of the replication fork. PHA-
767491 inhibits replication initiation by inhibiting CDC7/DBF4. Bleomycin induces double-stranded 
DNA breaks, while KU0055933 is an ATM inhibitor and it interferes with the DNA damage 
response. 
Our results show no increase in sensitivity in the RECQL4 deficient cells in comparison to the 
control cell lines. These results support the results obtained by Cabral et al. (2008) that there was 
no significant increase in sensitivity of the RECQL4 deficient cells in comparison to the controls 
when treated with Mitomycin C and Hydroxy Urea. When treated with Hydroxy Urea and 
Camptothecin, the lower passage shRQ-10 knockdown appears to have a slightly decreased 
sensitivity in comparison to the healthy OD and ASC cells. These results are contrary to those 
obtained in a study by Jin et al. (2008) that showed RTS fibroblasts were more sensitive to 
Hydroxy Urea and Camptothecin in comparison to their controls. Differences in results could be 
due to the different systems and models used to mimic RTS RECQL4 deficient cells. However, as 
seen above in sections 3.1 and 4.1, the most likely cause for the inconsistencies is the nature of 
the mutations and residual expression. The PHA-767491 sensitivity assay shows a dip at 0.25µM 
and 0.5μM for P44 shRQ-9. This result may be promising if real; in earlier studies in our laboratory 
increased sensitivity of the RECQL4 deficient RTS fibroblast cell line AG05013 to PHA-767491 was 
demonstrated (Tammy Wiltshire, personal communication). However, this sudden decrease could 
also be due to pipetting errors in those wells meaning there were not enough cells to pick up cell 
proliferation again, rather than the effects of the PHA-767491 itself.  
Chromosomal analysis 
Osteosarcomas normally see a number of chromosome alterations and genomic instability with 
aneuploidy being a common feature within cells in osteosarcoma patients (Nishijo et al., 2004). 
Chromosome instability is also a characteristic of RTS cell lines. Chromosomes were prepared 
from all nine of the cell lines used in this study and their chromosome number counted from 
around 35 cells. The chromosomes were also thoroughly examined for any obvious structural 
defects. As most previous studies show, aneuploidy exists in all RECQL4 deficient cells lines, but it 
is also seen in control cell lines. However, the degree of aneuploidy in both of the higher passage 
RECQL4 deficient cell lines and the OD+PHA cell line is greater, and contain cells with a tetraploid 
modal number of chromosomes. A study by Muff et al. (2015) reported that the gene expression 
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signature osteosarcoma cells is difficult to determine with stochastic chromosomal instability 
playing a key role in altered gene expressions. None of the cell lines show signs of chromosomal 
defects detectable by the techniques we used. Breakage analysis conducted by Smida et al. (2017) 
shows unstable regions in osteosarcoma in tumour suppressor genes such as TP53 and RB1. 
Comparative analysis of osteosarcoma-derived cell lines suggests that chromosomal instability 
arises from chromatin modifications at specific genomic locations in the osteosarcoma. Further 
tests would need to be conducted to evaluate whether our results support any of these findings.  
  
RECQL4: linking DNA replication to bone tumorigenesis 
 
 
74 
 
5. Conclusion and further research 
Multiple experiments were carried out in this study to determine whether there are any 
differences in chromosomal instabilities, sensitivity to genotoxic agents, differentiation potential 
and level of expression of marker genes between RECQL4 deficient ASC52Telo and control cells. 
Although we found no significant differences in growth characteristics, marker expression and 
drug sensitivity, the degree of numerical chromosomal instabilities was found to be greater in 
RECQL4 deficient cells. Slight differences could be seen in some of the results, but without 
confirmation that there is no residual RECQL4 expression in the knockdowns, it cannot be 
confirmed that the results are due to RECQL4 depletion.  
There are some improvements and variations that could be considered for future development of 
this experiment. These could benefit both the accuracy of the experiment, and the depth of 
information obtained. 
To better clarify RECQL4 expression in the shRNA knockdowns, a repeat of the western with a 
better RECQL4 antibody needs to be carried out. Patient derived cell lines from RTS patients with 
confirmed RECQL4 depletion could also be used to ensure RECQL4 depleted cells are being used.  
A popular method of analysing chromosomes is using spectral karyotyping (SKY). If a collaborator 
could be found, the samples obtained from these cells lines could be sent to be analysed to gain 
more accurate results and see if any chromosomal alterations can be identified. SKY staining of 
these chromosomal preparations would unravel structural chromosomal rearrangements at much 
higher sensitivity and resolution, and would also increase confidence in analysing numerical 
abnormalities. Chromosomes could also be prepared from RECQL4 depleted cells treated with the 
genotoxic agents to see if any obvious abnormalities can be seen when DNA damage is 
stimulated.  Immunofluorescence staining could also be repeated on RECQL4 depleted cells 
treated with the genotoxic agents to evaluate the expression DNA damage response markers.  
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